ArticleMethodsX2019
Determine the prevalence of gestational diabetes in Ardakan and its related factors.
Article in MethodsX, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 4 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gestational Diabetes (GD) is amongst the most common metabolic disorders. Due to the important complications of GD on maternal and fetal health and in order to identify the prevalence of GD in various climate and cultures, the present studies aimed to determine the prevalence of GD in Ardakan and its related factors in 2014-2015. This cross-sectional study was conducted in 3808 pregnant women referring to rural and urban health centers in Ardakan city in 2013-14. Demographic, clinical, and obstetrics history of the subjects was gathered. GD was defined based on Glucose Tolerance Test (GTT). Descriptive and Logistic regression models were applied. The prevalence of GD was estimated to be 7.5% (286) which was higher in 35-39 age group, urban residents, obese mothers, and pregnancies ended with macrosome babies. The odds of GD was higher in obese mothers by 1.62 times (95%CI: 1.18-2.24), in mothers above ages of 40 by 10.53 (95%CI: 3.8-29.3), in mothers with a history of GD by 3.86 (95%CI:1.65-8.93), and in pregnancies ended with a macro some baby by 2.2 (95%CI: 0.97-5.1). The prevalence of GD in Ardakan was similar to other studies in the area. It seems that improvement of GD screening in older mothers and those with a history of GD could be a priority of surveillance system in Yazd Province.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.